• About us
    • About ImaBiotech
    • Our team
    • Quality Engagement
    • Careers
    • Contact Imabiotech
  • Innovative platforms
    • Overview of Technologies
    • Mass Spectrometry Imaging
    • Laser Microdissection
    • Multimaging™ Software
    • Spatially Resolved Gene Expression
    • High Multiplexing Proteins & Cell Markers
    • Testing Panels
  • Therapeutic areas
    • Oncology
    • Dermatology
    • Ophthalmology
    • Respiratory diseases
    • Central Nervous System
    • Metabolic Disorders
  • Services
    • Overview of Services
    • Biodistribution
    • Biomarkers Discovery
    • Formulation Screening
    • Digital Pathology Services
    • Drug Delivery
    • PK/PD-Pharmacology
    • Safety support
    • Translational Research
    • Clinical Drug Efficacy
  • Resources
    • Conferences and Webinars
    • Articles and research
    • Press releases & In the Press
    • Imabiotech news

Author: Fabien Pamelard

  • Fluidigm announces collaboration agreement with Imaging CRO ImaBiotech to increase biopharma access to Imaging Mass Cytometry

  • Mass spectrometry Imaging skin tissue compared to histological tissue

    Following toxicity and efficacy markers in skin substructures using Mass Spectrometry Imaging (MSI)

  • Mass Spectrometry imaging in Brain

    Metabolomics and Metabolite Profiling using Mass Spectrometry Imaging (MSI): A New Biochemical Tool for Drug Discovery

  • Imaging mass spec

    Quantitative Mass Spectrometry Imaging (QMSI) of endogenous insulin in mouse pancreas using modified Insulin

Search news




© ImaBiotech 2018-2022

Build Your Pathway